Associated Myocarditis: A Predictive Factor for Response?

Walid Shalata, Nir Peled, Itzhak Gabizon, Omar Abu Saleh, Waleed Kian, Alexander Yakobson

    Research output: Contribution to journalArticlepeer-review

    12 Scopus citations


    In the present case report, we aimed to describe 2 cases of myocarditis occurring as serious adverse effects of immune checkpoint inhibitors (ICIs) administered as treatment for metastatic melanoma. We describe 2 female patients: an 81-year-old treated with pembrolizumab and a 55-year-old treated with a combination of nivolumab and ipilimumab. Both patients underwent resection of metastases; while under treatment, both developed myocarditis, most probably as a toxicity from pembrolizumab and nivolumab plus Ipilimumab, respectively. While they achieved complete response, the occurrence of myocarditis as a toxicity of ICIs may have been a predictive sign that the immune system was sufficiently activated by the checkpoint inhibitor therapy to induce complete remission.

    Original languageEnglish
    Pages (from-to)550-557
    Number of pages8
    JournalCase Reports in Oncology
    Issue number2
    StatePublished - 1 Jan 2020


    • Immune checkpoint inhibitors
    • Ipilimumab
    • Melanoma
    • Myocarditis
    • Nivolumab
    • Pembrolizumab

    ASJC Scopus subject areas

    • Oncology


    Dive into the research topics of 'Associated Myocarditis: A Predictive Factor for Response?'. Together they form a unique fingerprint.

    Cite this